Company

Life Biosciences

Last updated 2026-05-30· 1 min read

Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.

What it is

Life Biosciences (founded 2017) is a holding company spawning operating subsidiaries focused on different mechanisms of aging:

Cellular reprogramming (now the main programme).
Senescence (early on).
Mitochondrial focus.
Stem-cell biology.

Current focus

Partial Yamanaka-factor reprogramming via AAV gene therapy. Lead programmes in vision restoration (glaucoma, non-arteritic anterior ischaemic optic neuropathy / NAION) building on David Sinclair’s 2020 Nature paper showing OSK restored vision in mouse glaucoma.

Pipeline state

Pre-clinical to early-clinical. First-in-human trials planned in ophthalmology indications where local AAV delivery has favourable risk-benefit and where Sinclair’s mouse work showed clear effects.

Notable

David Sinclair on scientific advisory board / co-founder.
Has spun out and consolidated multiple subsidiaries over its history.

Model and current focus

Life Biosciences was founded as a multi-programme longevity biotech targeting the hallmarks of aging with an operating-company model. More recently, it has narrowed focus to partial cellular reprogramming and epigenetic-restoration approaches — a strategic consolidation reflecting the field's convergence on reprogramming as a high-conviction pillar.

Programmes

Er2/Er3 platform: transcription-factor-based reprogramming aimed at optic-nerve indications (age-related macular degeneration, glaucoma).
Systemic reprogramming platform: earlier-stage work on systemic OSK delivery.

Position

Life Biosciences sits alongside Altos Labs, NewLimit, Retro, and Turn.bio in the partial-reprogramming cohort of the current wave of longevity biotechs. Each has picked a slightly different lead-indication strategy.